Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026
Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform
Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025
Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities
Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
Novo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital
Investor Alert: Abbott Cooper PLLC Announces Investigation into Paratek Pharmaceuticals, Inc.; Urges Paratek Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million
Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital
NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital
Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
7 Growth Stocks That Are Too Cheap to Ignore Right Now
Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9
Paratek Pharmaceuticals, Inc. (PRTK) Q4 2022 Earnings Call Transcript
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16
Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates
Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference
Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3
Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q2 2022 Results - Earnings Call Transcript
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
Paratek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
What to Know About Buying Penny Stocks on June 22nd
Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference
Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2022 Results - Earnings Call Transcript
Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2021 Results - Earnings Call Transcript
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022
Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2021 Results - Earnings Call Transcript
Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021
Paratek Secures BARDA Funding To Develop Nuzyra Antibiotic For Pulmonary Anthrax
Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax